

101.113-24/04 – including *Taq* polymerase
101.113-24u/04u – without *Taq* polymerase

Visit www.caredx.com for
“Instructions for Use” (IFU)

Lot No.: **7R2**

Lot-specific information

Olerup SSP[®] DRB1*03

Product number:	101.113-24/04 – including <i>Taq</i> pol. 101.113-24u/04u – without <i>Taq</i> pol.
Lot number:	7R2
Expiry date:	2027-02-01
Number of tests:	24 tests – Product No. 101.113-24/24u 4 tests – Product No. 101.113-04/04u
Number of wells per test:	31+1
Storage - pre-aliquoted primers:	dark, between -15°C and -25°C
- PCR Master Mix:	between -15°C and -25°C
- Adhesive PCR seals	RT

This Product Description is only valid for Lot No. 7R2.

Complete product documentation consists of generic Instructions for Use (IFU), lot specific Product Insert, Worksheet and Certificate.

CHANGES COMPARED TO THE PREVIOUS OLERUP SSP[®] DRB1*03 LOT (4N8)

- The product documentation has been updated for new alleles of IMGT 3.50.0
- The kit resolution focuses on common and well documented (CWD) alleles¹.

¹As described in section Uniquely Identified Alleles.

The DRB1*03 primer set, specificity and interpretation tables have been updated for the DRB1 alleles described since the previous *Olerup SSP[®] DRB1*03* lot was made (**Lot No. 4N8**).

The DRB1*03 primer set is unchanged compared to the previous lot (**Lot No. 4N8**).

¹S. J. Mack, P. Cano, J. A. Hollenbach et al.
Common and well-documented HLA alleles: 2012 update to
the CWD catalogue. Tissue Antigens, 2013, 81, 194–203



0197

For *In Vitro* Diagnostic Use
MA123 v02 SSP PI Template
Date: March 2023, Rev. No:00

101.113-24/04 – including *Taq* polymerase

101.113-24u/04u – without *Taq* polymerase

Lot No.: **7R2**

Lot-specific information

Visit www.caredx.com for
“Instructions for Use” (IFU)

Well **32** contains Negative Control primer pairs, that will amplify a majority of the *Olerup SSP*® HLA Class I, DRB, DQB1, DPB1 and DQA1 amplicons as well as all the amplicons generated by the control primer pairs matching the human growth hormone gene.

HLA-specific PCR product sizes range from 75 to 200 base pairs.
The PCR product generated by the positive control primer pair is 200 base pairs.

Length of PCR product	105	200	105	80	75	80	85
5'-primer¹	164	340	440	45	45	43	36
	5'-CAC ^{3'}	5'-Agg ^{3'}	5'-TTA ^{3'}	5'-Tgg ^{3'}	5'-Tgg ^{3'}	5'-Tgg ^{3'}	5'-TAC ^{3'}
							36
							5'-TAT ^{3'}
3'-primer²	231	2nd I	507	59	58	57	47
	5'-TgC ^{3'}	5'-AAA ^{3'}	5'-TTg ^{3'}	5'-CTC ^{3'}	5'-ggC ^{3'}	5'-CTC ^{3'}	5'-ACA ^{3'}
							48
							5'-gCA ^{3'}
							48
							5'-gCC ^{3'}
							52
							5'-TgT ^{3'}
A*	+	+	+				
B*	+	+	+				
C*	+	+	+				
DRB1				+	+		
DRB3				+	+		
DRB5				+			
DQB1					+		
DPB1						+	
DQA1							+

¹The nucleotide position for HLA class I genes and the codon for HLA class II genes, in the 2nd or 3rd exon, matching the specificity-determining 3'-end of the primer is given. Nucleotide and codon numbering as on the www.ebi.ac.uk/imgt/hla web site. The sequence of the 3 terminal nucleotides of the primer is given.

²The nucleotide position for HLA class I genes and the codon for HLA class II genes, in the 2nd or 3rd exon or the 2nd intron, matching the specificity-determining 3'-end of the primer is given in the anti-sense direction. Nucleotide and codon numbering as on the www.ebi.ac.uk/imgt/hla web site. The sequence of the 3 terminal nucleotides of the primer is given.



0197

For *In Vitro* Diagnostic Use
MA123 v02 SSP PI Template
Date: March 2023, Rev. No:00

101.113-24/04 – including *Taq* polymerase

101.113-24u/04u – without *Taq* polymerase

Lot No.: **7R2**

Visit www.caredx.com for
“Instructions for Use” (IFU)

Lot-specific information

PRODUCT DESCRIPTION

DRB1*03 SSP subtyping

CONTENT

The primer set contains 5'- and 3'-primers for identifying the DRB1*03:01 to DRB1*03:203 alleles.

PLATE LAYOUT

Each test consists of 32 PCR reactions in a 32 well cut PCR plate.

Note: This lot was manufactured using white plastic trays.

1	2	3	4	5	6	7	8
9	10	11	12	13	14	15	16
17	18	19	20	21	22	23	24
25	26	27	28	29	30	31	NC

The 32 well cut PCR plate is marked with ‘DRB1*03’ in silver/gray ink.

Well No. 1 is marked with the Lot No. ‘7R2’.

Wells 1 to 31 – DRB1*03 high resolution primers.

Well 32 – Negative Control (NC).

A faint row of numbers is seen between wells 1 and 2 or wells 7 and 8 of the PCR trays.

These stem from the manufacture of the trays, and should be disregarded.

The PCR plates are heat-sealed with a PCR-compatible foil.

Please note: When removing each 32 well PCR plate, make sure that the remaining plates stay sealed. Use a scalpel or a similar instrument to carefully cut the foil between the plates.

INTERPRETATION

Due to the sharing of sequence motifs within the DR52 group of DRB1 alleles, non-DRB1*03 alleles will be amplified by primer some mixes. For further details see Specificity Table.

UNIQUELY IDENTIFIED ALLELES

All the phenotypically different DRB1*03 alleles, i.e. **DRB1*03:01 to DRB1*03:203**, recognized by the HLA Nomenclature Committee in October 2022^{1,2} will be amplified by the primers in the DRB1*03 subtyping kit³.

The DRB1*03 kit enables separation of the confirmed DRB1*03 alleles as listed in the IMGT/HLA database 3.26.0. An HLA allele is listed as confirmed by IMGT/HLA if it has been sequenced by more than a single laboratory or from multiple sources. Current allele confirmation status for DRB1*03 alleles is listed below.

The DRB1*03 kit also enables identification of many null and alternatively expressed alleles.



0197

For *In Vitro* Diagnostic Use
MA123 v02 SSP PI Template
Date: March 2023, Rev. No:00

101.113-24/04 – including *Taq* polymerase

101.113-24u/04u – without *Taq* polymerase

Lot No.: 7R2

Lot-specific information

Visit www.caredx.com for
“Instructions for Use” (IFU)

The following DRB1*03 alleles can be distinguished by the different sizes of the specific PCR product:

Alleles	Primer mix
DRB1*03:18, 03:48	22
DRB1*03:20, 03:93	17

¹DRB1 alleles listed on the IMGT/HLA web page 2022-October-12, release 3.50.0, www.ebi.ac.uk/imgt/hla.

²Alleles that have been deleted from or renamed in the official WHO HLA Nomenclature up to and including the last IMGT/HLA database release can be retrieved from web page <http://hla.alleles.org/alleles/deleted.html>.

³The DRB1*03 primer set cannot separate the following alleles. These alleles can be distinguished by the DR low resolution kit and/or the DRB1*14 high resolution kit:

Alleles

DRB1*03:35, DRB1*14:127:01-14:127:02

DRB1*03:97, DRB1*14:33

DRB1*03:126, 03:191, DRB1*14:95

RESOLUTION IN HOMO- AND HETEROZYGOTES

Results file with resolution in DRB1*03 homo- and heterozygotes is available upon request.



0197

For *In Vitro* Diagnostic Use
MA123 v02 SSP PI Template
Date: March 2023, Rev. No:00

101.113-24/04 – including *Taq* polymerase

101.113-24u/04u – without *Taq* polymerase

Lot No.: **7R2**

Lot-specific information

Visit www.caredx.com for
“Instructions for Use” (IFU)

ALLELE CONFIRMATION STATUS

Allele	Status ¹	Allele	Status ¹	Allele	Status ¹	Allele	Status ¹
DRB1*03:01:01:01	Confirmed	DRB1*03:19	Confirmed	DRB1*03:68N	Unconfirmed	DRB1*03:116	Unconfirmed
DRB1*03:01:01:02	Unconfirmed	DRB1*03:20	Unconfirmed	DRB1*03:69	Unconfirmed	DRB1*03:117	Unconfirmed
DRB1*03:01:02	Confirmed	DRB1*03:21	Confirmed	DRB1*03:70	Unconfirmed	DRB1*03:118	Unconfirmed
DRB1*03:01:03	Unconfirmed	DRB1*03:22	Confirmed	DRB1*03:71:01	Confirmed	DRB1*03:119	Unconfirmed
DRB1*03:01:04	Unconfirmed	DRB1*03:23	Confirmed	DRB1*03:71:02	Unconfirmed	DRB1*03:120	Unconfirmed
DRB1*03:01:05	Unconfirmed	DRB1*03:24	Unconfirmed	DRB1*03:72	Confirmed	DRB1*03:121	Unconfirmed
DRB1*03:01:06	Unconfirmed	DRB1*03:25	Unconfirmed	DRB1*03:73	Unconfirmed	DRB1*03:122	Unconfirmed
DRB1*03:01:07	Confirmed	DRB1*03:26	Unconfirmed	DRB1*03:74	Unconfirmed	DRB1*03:123	Unconfirmed
DRB1*03:01:08	Unconfirmed	DRB1*03:27	Confirmed	DRB1*03:75	Unconfirmed	DRB1*03:124	Confirmed
DRB1*03:01:09	Unconfirmed	DRB1*03:28	Unconfirmed	DRB1*03:76	Confirmed	DRB1*03:125	Unconfirmed
DRB1*03:01:10	Unconfirmed	DRB1*03:29	Confirmed	DRB1*03:77	Unconfirmed	DRB1*03:126	Unconfirmed
DRB1*03:01:11	Confirmed	DRB1*03:30	Unconfirmed	DRB1*03:78	Unconfirmed	DRB1*03:127	Unconfirmed
DRB1*03:01:12	Confirmed	DRB1*03:31	Unconfirmed	DRB1*03:79	Unconfirmed	DRB1*03:128	Unconfirmed
DRB1*03:01:13	Unconfirmed	DRB1*03:32	Unconfirmed	DRB1*03:80	Unconfirmed	DRB1*03:129	Unconfirmed
DRB1*03:01:14	Confirmed	DRB1*03:33	Confirmed	DRB1*03:81	Unconfirmed	DRB1*03:130	Unconfirmed
DRB1*03:01:15	Confirmed	DRB1*03:34	Confirmed	DRB1*03:82	Unconfirmed	DRB1*03:131	Unconfirmed
DRB1*03:01:16	Confirmed	DRB1*03:35	Unconfirmed	DRB1*03:83	Unconfirmed	DRB1*03:132	Unconfirmed
DRB1*03:01:17	Confirmed	DRB1*03:36	Unconfirmed	DRB1*03:84	Unconfirmed	DRB1*03:133	Unconfirmed
DRB1*03:01:18	Unconfirmed	DRB1*03:37	Confirmed	DRB1*03:85	Unconfirmed	DRB1*03:134	Unconfirmed
DRB1*03:01:19	Unconfirmed	DRB1*03:38	Unconfirmed	DRB1*03:86	Unconfirmed	DRB1*03:135	Unconfirmed
DRB1*03:01:20	Confirmed	DRB1*03:39	Unconfirmed	DRB1*03:87	Unconfirmed	DRB1*03:136	Unconfirmed
DRB1*03:01:21	Unconfirmed	DRB1*03:40	Unconfirmed	DRB1*03:88	Confirmed		
DRB1*03:01:22	Unconfirmed	DRB1*03:41:01	Unconfirmed	DRB1*03:89	Unconfirmed		
DRB1*03:01:23	Unconfirmed	DRB1*03:41:02	Unconfirmed	DRB1*03:90	Confirmed		
DRB1*03:01:24	Unconfirmed	DRB1*03:42	Confirmed	DRB1*03:91	Unconfirmed		
DRB1*03:01:25	Unconfirmed	DRB1*03:43	Confirmed	DRB1*03:92	Unconfirmed		
DRB1*03:02:01	Confirmed	DRB1*03:44	Confirmed	DRB1*03:93	Confirmed		
DRB1*03:02:02	Confirmed	DRB1*03:45	Unconfirmed	DRB1*03:94	Unconfirmed		
DRB1*03:02:03	Unconfirmed	DRB1*03:46	Unconfirmed	DRB1*03:95	Unconfirmed		
DRB1*03:03	Confirmed	DRB1*03:47	Confirmed	DRB1*03:96	Unconfirmed		
DRB1*03:04:01	Confirmed	DRB1*03:48	Confirmed	DRB1*03:97	Unconfirmed		
DRB1*03:04:02	Unconfirmed	DRB1*03:49	Unconfirmed	DRB1*03:98	Unconfirmed		
DRB1*03:05:01	Confirmed	DRB1*03:50	Confirmed	DRB1*03:99	Unconfirmed		
DRB1*03:05:02	Unconfirmed	DRB1*03:51	Unconfirmed	DRB1*03:100:01	Unconfirmed		
DRB1*03:05:03	Confirmed	DRB1*03:52	Unconfirmed	DRB1*03:100:02	Unconfirmed		
DRB1*03:06	Confirmed	DRB1*03:53	Confirmed	DRB1*03:101	Unconfirmed		
DRB1*03:07	Confirmed	DRB1*03:54	Unconfirmed	DRB1*03:102	Unconfirmed		
DRB1*03:08	Confirmed	DRB1*03:55	Confirmed	DRB1*03:103	Unconfirmed		
DRB1*03:09	Unconfirmed	DRB1*03:56	Unconfirmed	DRB1*03:104	Unconfirmed		
DRB1*03:10	Unconfirmed	DRB1*03:57	Unconfirmed	DRB1*03:105	Unconfirmed		
DRB1*03:11:01	Unconfirmed	DRB1*03:58	Confirmed	DRB1*03:106	Unconfirmed		
DRB1*03:12	Unconfirmed	DRB1*03:59	Unconfirmed	DRB1*03:107	Unconfirmed		
DRB1*03:13:01	Confirmed	DRB1*03:60	Unconfirmed	DRB1*03:108	Unconfirmed		
DRB1*03:13:02	Confirmed	DRB1*03:61	Unconfirmed	DRB1*03:109	Unconfirmed		
DRB1*03:14	Confirmed	DRB1*03:62	Confirmed	DRB1*03:110	Confirmed		
DRB1*03:15:01	Confirmed	DRB1*03:63	Unconfirmed	DRB1*03:111	Unconfirmed		
DRB1*03:15:02	Unconfirmed	DRB1*03:64	Unconfirmed	DRB1*03:112	Confirmed		
DRB1*03:16	Confirmed	DRB1*03:65	Confirmed	DRB1*03:113	Unconfirmed		
DRB1*03:17	Unconfirmed	DRB1*03:66	Unconfirmed	DRB1*03:114	Unconfirmed		
DRB1*03:18	Unconfirmed	DRB1*03:67N	Unconfirmed	DRB1*03:115	Confirmed		

¹Allele status “confirmed” or “unconfirmed” as listed on the IMGT/HLA web page 2016-October-14, release 3.26.0, www.ebi.ac.uk/imgt/hla.



0197

For *In Vitro* Diagnostic Use
MA123 v02 SSP PI Template
Date: March 2023, Rev. No:00

101.113-24/04 – including *Taq* polymerase

101.113-24u/04u – without *Taq* polymerase

Lot No.: **7R2**

Visit www.caredx.com for
“Instructions for Use” (IFU)

Lot-specific information

SPECIFICITY TABLE

DRB1*03 SSP subtyping

Specificities and sizes of the PCR products of the 31+1 primer mixes used for DRB1*03 SSP subtyping

Primer Mix	Size of spec. PCR product ¹	Size of control band ²	Amplified DRB1*03 alleles ³	Other amplified DRB alleles
1	220 bp	515 bp	*03:01:01:01-03:01:41, 03:04:01-03:04:02, 03:06, 03:08, 03:10-03:11:01, 03:11:03-03:13:02, 03:15:01:01-03:16, 03:18-03:20, 03:22-03:23, 03:25:01-03:26, 03:28, 03:30-03:34, 03:36-03:37, 03:39, 03:42-03:48, 03:50-03:52:02, 03:55-03:56, 03:58-03:62, 03:64-03:73, 03:75-03:80, 03:82-03:87, 03:89, 03:91-03:96, 03:98-03:100:02, 03:104, 03:106-03:112, 03:114, 03:116-03:118, 03:121, 03:124-03:129, 03:132-03:153, 03:156N-03:166, 03:168-03:170, 03:172-03:175, 03:177, 03:180-03:184, 03:186-03:187, 03:189N-03:203	*09:06, 11:59, 11:83, 11:135, 11:182, 13:27:01-13:27:02, 13:71, 13:129, 13:144, 13:176, 13:326, 14:82, 14:95, 14:132, DRB3*01:34, DRB3*03:33
2 ^{4,6}	85 bp	430 bp	*03:02:01:01-03:03, 03:27, 03:29, 03:38, 03:53, 03:74, 03:88, 03:90, 03:102-03:103, 03:115, 03:119, 03:131, 03:154, 03:167, 03:176, 03:179	*13:15, 13:19, 13:26:01-13:26:02, 13:53, 13:57, 13:85-13:86, 13:104, 13:198, 13:235, 14:02:01:01-14:03:02, 14:06:01-14:06:06, 14:12:01-14:13, 14:18-14:20, 14:24, 14:27:01-14:27:02, 14:29, 14:40-14:41, 14:47-14:49, 14:51, 14:63, 14:67, 14:77-14:78, 14:81, 14:83, 14:85, 14:89, 14:94, 14:98, 14:102, 14:106, 14:108-14:109, 14:115, 14:135, 14:154, 14:156, 14:159-14:160, 14:165, 14:170, 14:174, 14:176-14:177, 14:181, 14:194-14:195N, 14:198, 14:200, 14:209, 14:212, 14:218, 14:222N-14:223, 14:226, 14:239, 14:242
3	155 bp	515 bp	*03:97, 03:126, 03:191	*13:302, 14:18, 14:33, 14:51, 14:59, 14:64, 14:95, 14:106, 14:132-14:134, 14:154, 14:246
	190 bp		*03:02:01:01-03:02:06, 03:05:01-03:05:03, 03:09, 03:14, 03:27, 03:29, 03:38, 03:53, 03:74, 03:81, 03:88, 03:90, 03:102-03:103,	*11:09:01:01-11:09:01:02, 11:20, 11:28:02, 11:87, 11:122, 13:02:01:01-13:02:03, 13:02:05-13:02:22, 13:05:01:01-13:05:03, 13:26:01-13:26:02, 13:29:01:01-13:29:01:02, 13:31, 13:34, 13:36, 13:39, 13:41, 13:50:02-13:50:03, 13:56, 13:63, 13:65, 13:67,



0197

For *In Vitro* Diagnostic Use
MA123 v02 SSP PI Template
Date: March 2023, Rev. No:00

101.113-24/04 – including *Taq* polymerase

101.113-24u/04u – without *Taq* polymerase

Visit www.caredx.com for
“Instructions for Use” (IFU)

Lot No.: **7R2**

Lot-specific information

			03:115, 03:122, 03:130-03:131, 03:154, 03:167, 03:176, 03:178-03:179, 03:188	13:73-13:74, 13:85, 13:96:01-13:96:02, 13:99, 13:103-13:104, 13:119-13:120, 13:123-13:124, 13:126, 13:128, 13:136, 13:139-13:140, 13:142N-13:143, 13:145, 13:147, 13:155, 13:157-13:159, 13:165, 13:168, 13:170-13:171:02, 13:179, 13:189, 13:196, 13:198-13:199, 13:202-13:203, 13:207-13:212, 13:220, 13:225, 13:235-13:237, 13:239-13:241, 13:243-13:244, 13:255N, 13:257, 13:264-13:265, 13:268N-13:269, 13:275, 13:277, 13:280, 13:282, 13:285, 13:288-13:289N, 13:292-13:293, 13:296-13:298N, 13:301-13:302, 13:306, 13:310N, 13:318, 13:320, 13:325, 13:331-13:332, 14:02:01:01-14:02:07, 14:02:09-14:03:02, 14:09, 14:13, 14:19, 14:24, 14:27:01-14:27:02, 14:30, 14:46-14:48, 14:51, 14:63, 14:67, 14:85, 14:89, 14:98, 14:109, 14:115, 14:134-14:135, 14:144, 14:174, 14:179, 14:194, 14:198, 14:200, 14:209, 14:218, 14:222N-14:223, 14:226, 14:239, 14:242, 16:08, DRB3*01:08, DRB3*01:46, DRB3*01:52, DRB3*01:71, DRB3*02:06, DRB3*02:20
4	190 bp	515 bp	*03:01:01:01-03:01:41, 03:03, 03:06-03:08, 03:10-03:11:01, 03:11:03-03:13:02, 03:15:01:01-03:16, 03:18-03:20, 03:22-03:24, 03:26, 03:28, 03:32-03:34, 03:36-03:37, 03:39, 03:42, 03:45-03:48, 03:50-03:51, 03:52:02, 03:54-03:56, 03:58-03:62, 03:64-03:73, 03:76-03:80, 03:82-03:87, 03:89, 03:91-03:101, 03:104, 03:106-03:114, 03:116-03:117, 03:119-03:121, 03:124-03:129, 03:132-03:153, 03:156N-03:166, 03:168-03:175, 03:177, 03:180-03:187, 03:189N-03:203	*04:211, 04:230, 11:16:01:01-11:16:01:02, 11:40, 11:58:01, 11:59, 11:83, 11:113, 11:115, 11:182, 11:280, 12:58, 13:01:01:01-13:01:39, 13:06, 13:09-13:10, 13:15, 13:18, 13:20:01:01-13:20:01:03, 13:27:01-13:28:02, 13:32, 13:35, 13:40, 13:42:01-13:43, 13:51, 13:53, 13:59, 13:61:01-13:61:02, 13:69, 13:71, 13:77-13:80, 13:87, 13:91-13:93, 13:98, 13:102, 13:105, 13:110-13:114, 13:117:01:01-13:117:01:02, 13:121, 13:125, 13:127, 13:129-13:131, 13:137N-13:138, 13:141, 13:144, 13:146, 13:148, 13:153, 13:156, 13:160, 13:163, 13:166, 13:173, 13:176-13:178, 13:181, 13:183-13:187, 13:190-13:193, 13:200N-13:201, 13:205, 13:213-13:215, 13:217-13:218, 13:221-13:223, 13:226, 13:233, 13:238, 13:242:01-13:242:02, 13:245, 13:248-13:249N, 13:251-13:252N, 13:254, 13:256, 13:258-13:263, 13:266-13:267, 13:270-13:274, 13:279, 13:281, 13:283, 13:287, 13:291, 13:294, 13:299-13:300, 13:303-13:305, 13:308-13:309, 13:311, 13:313, 13:322N-13:324N, 13:326-13:328, 14:06:01-14:06:06, 14:12:01-14:12:02, 14:17-14:18, 14:21, 14:29, 14:33, 14:52, 14:59, 14:64, 14:78, 14:80-14:81, 14:83, 14:95, 14:106, 14:108, 14:121, 14:132-14:133, 14:154, 14:165, 14:170, 14:176-14:177, 14:195N, 14:212, 14:246, 15:32, 15:192, DRB3*03:10
5⁴	75 bp	430 bp	*03:04:01-03:04:02	
6^{4,5}	105 bp	430 bp	*03:01:01:01-03:01:41, 03:04:01-03:05:03,	*11:59, 11:80, 11:87, 11:135, 11:142, 11:182, 13:27:01-13:27:02, 13:41, 13:71,



0197

For *In Vitro* Diagnostic Use
MA123 v02 SSP PI Template
Date: March 2023, Rev. No:00

101.113-24/04 – including *Taq* polymerase
101.113-24u/04u – without *Taq* polymerase

Visit www.caredx.com for
“Instructions for Use” (IFU)

Lot No.: **7R2**

Lot-specific information

			03:08-03:11:01, 03:11:03-03:16, 03:18- 03:20, 03:22-03:23, 03:25:01-03:25:02, 03:28, 03:30, 03:32- 03:34, 03:36-03:37, 03:39, 03:42-03:48, 03:50-03:52:02, 03:55- 03:59, 03:61-03:73, 03:76-03:79, 03:81, 03:83-03:84, 03:86- 03:87, 03:89, 03:91- 03:96, 03:98-03:100:02, 03:104, 03:106-03:112, 03:114, 03:116-03:118, 03:121, 03:123-03:130, 03:132-03:137, 03:139- 03:153, 03:156N- 03:157, 03:159-03:166, 03:168-03:170, 03:172- 03:175, 03:177, 03:180, 03:182-03:184, 03:186- 03:187, 03:189N-03:203	13:129, 13:144, 13:176, 13:277, 13:326, 14:95, 14:132, 14:179, DRB3*01:23, DRB3*01:46
7⁴	125 bp 150 bp 215 bp	430 bp	*03:08, 03:65, 03:72 03:140 *03:124 *03:132	*11:59, 11:80, 11:83, 11:87, 11:135, 11:142, 11:182, DRB3*01:42 *04:02:07, DRB5*01:04[?]
8	185 bp	430 bp	*03:02:01:01-03:03, 03:07:01:01-03:07:02, 03:21, 03:29, 03:38, 03:40-03:41:02, 03:49, 03:53, 03:74, 03:88, 03:101-03:103, 03:105, 03:115, 03:119-03:120, 03:131, 03:154-03:155, 03:171, 03:176, 03:178- 03:179	*01:16, 01:55, 01:101, 04:22, 04:283, 11:07:01-11:07:02, 11:103:01-11:103:02, 11:107, 11:125, 11:173, 14:76, 14:79, 14:171, 15:25, DRB3*01:09, DRB3*01:36, DRB3*01:71, DRB3*02:04, DRB3*02:19, DRB3*02:22:01-02:22:02, DRB3*02:56, DRB3*02:146, DRB3*03:03-03:04:02
9	135 bp	430 bp	*03:01:01:01-03:01:41, 03:04:01-03:06, 03:09, 03:11:01, 03:11:03, 03:13:01 ^w -03:13:02 ^w , 03:14-03:16, 03:18- 03:20, 03:22-03:23, 03:25:01-03:26, 03:28, 03:30-03:34, 03:36- 03:37, 03:39, 03:42- 03:45, 03:47-03:48, 03:50-03:52:02, 03:55- 03:63, 03:66, 03:67N ^w , 03:68N-03:73, 03:75- 03:78, 03:80-03:84, 03:86-03:87, 03:89, 03:91-03:95, 03:98- 03:100:02, 03:104, 03:106-03:109, 03:111- 03:112, 03:114, 03:116,	*09:01:08, 09:02:01-09:02:02, 09:42, 13:27:01-13:27:02, 13:41, 13:71, 13:129, 13:144, 13:176, 13:277, 13:326, 14:95, 14:179, DRB3*01:07, DRB3*01:15, DRB3*01:41, DRB3*01:50, DRB3*01:75^w, DRB3*01:76, DRB3*02:130, DRB3*02:134



0197

For *In Vitro* Diagnostic Use
MA123 v02 SSP PI Template
Date: March 2023, Rev. No:00

101.113-24/04 – including *Taq* polymerase
101.113-24u/04u – without *Taq* polymerase

Visit www.caredx.com for
“Instructions for Use” (IFU)

Lot No.: **7R2**

Lot-specific information

			03:117 ^w , 03:118, 03:121-03:129, 03:132- 03:139, 03:141-03:153, 03:157, 03:159-03:166, 03:168-03:170, 03:172- 03:175, 03:177, 03:180- 03:184, 03:186-03:187, 03:190-03:203	
10	145 bp	430 bp	*03:02:01:01-03:03, 03:06, 03:17, 03:26- 03:27, 03:31, 03:35, 03:38, 03:41:01- 03:41:02, 03:60, 03:74- 03:75, 03:80, 03:85, 03:88, 03:90, 03:102- 03:103, 03:115, 03:122, 03:131, 03:154-03:155, 03:158, 03:167, 03:176, 03:179	*08:20, 11:17, 11:37:01-11:37:02, 11:41, 11:48, 11:50, 11:52, 11:56, 11:83, 11:107, 11:145, 11:149, 11:170-11:171, 11:183- 11:184, 11:189, 11:200, 11:249, 11:264, 11:273, 13:03:01:01-13:03:12, 13:07:01- 13:08, 13:12:01-13:13, 13:19, 13:26:01- 13:26:02, 13:32-13:33:03, 13:36-13:38, 13:40, 13:47-13:49:02, 13:53, 13:55, 13:58, 13:60, 13:65, 13:70, 13:72, 13:76, 13:81, 13:84-13:85, 13:88-13:90, 13:94:01-13:95, 13:101, 13:108, 13:115, 13:118, 13:120, 13:122, 13:133-13:135, 13:149, 13:151- 13:152, 13:159, 13:164, 13:167, 13:174, 13:180, 13:182, 13:188-13:189, 13:191, 13:194, 13:198, 13:216, 13:219, 13:227- 13:228, 13:230-13:232, 13:235, 13:246, 13:253, 13:262, 13:295N, 13:307, 13:316- 13:317, 13:319N, 13:321, 13:329N, 14:01:01-14:03:01, 14:05:01:01-14:09, 14:12:01-14:14, 14:16, 14:18-14:20, 14:22- 14:27:02, 14:29, 14:32:01-14:32:03, 14:34, 14:36-14:41, 14:43-14:45, 14:47-14:49, 14:51, 14:54:01:01-14:56, 14:58-14:60, 14:62-14:63, 14:67, 14:69-14:70, 14:74- 14:75, 14:77-14:78, 14:80-14:92N, 14:94, 14:96-14:106, 14:108-14:119, 14:121- 14:125, 14:127:01-14:127:02, 14:129- 14:131, 14:133, 14:135-14:137N, 14:139- 14:140, 14:142, 14:144, 14:146-14:147, 14:149, 14:151, 14:153-14:174, 14:176- 14:178, 14:181, 14:183-14:185, 14:188N- 14:195N, 14:197N-14:198, 14:200, 14:202- 14:204, 14:207, 14:209, 14:211-14:219, 14:222N-14:223, 14:225-14:228, 14:230, 14:232, 14:234-14:240, 14:242-14:246, DRB3*01:14
11⁴	100 bp 125 bp 180 bp	515 bp	*03:09, 03:23, 03:112 *03:115 *03:13:01-03:13:02, 03:38, 03:79, 03:88, 03:167	*14:151 *11:116, 11:120, 13:39, 13:54, 13:77-13:79, 13:100, 13:162-13:163, 13:181, 14:48, 14:64, 14:109, 14:115, 14:177, DRB3*01:14
12	135 bp 190 bp	430 bp	*03:10, 03:110 *03:51, 03:76, 03:125, 03:174N	*14:82, 14:132 *11:59 ^w , 11:80 ^w , 11:83 ^w , 11:87 ^w , 11:135 ^w , 11:142 ^w , 11:182 ^w , 13:27:01 ^w -13:27:02 ^w , 13:41 ^w , 13:71 ^w , 13:129 ^w , 13:176 ^w , 13:277 ^w , 13:326 ^w , 14:179 ^w



0197

For *In Vitro* Diagnostic Use
MA123 v02 SSP PI Template
Date: March 2023, Rev. No:00

101.113-24/04 – including *Taq* polymerase
101.113-24u/04u – without *Taq* polymerase

Visit www.caredx.com for
“Instructions for Use” (IFU)

Lot No.: **7R2**

Lot-specific information

13⁴	125 bp 160 bp 225 bp	430 bp	*03:115 *03:47, 03:62 *03:11:01, 03:11:03, 03:17, 03:24, 03:27, 03:35, 03:81, 03:167, 03:177, 03:188	*14:151 *11:136, 14:38:01-14:38:02, 14:127:01- 14:127:02, 14:244
14⁴	105 bp 135 bp 245 bp	515 bp	*03:16 *03:12, 03:110, 03:158 *03:68N	*09:08 DRB3*01:77N
15⁴	95 bp 155 bp	430 bp	*03:112 *03:17, 03:37, 03:62, 03:80, 03:140	*11:39, 11:43:01:01-11:43:01:02, 11:50, 11:115, 11:145, 11:151, 11:168, 11:171, 11:174, 13:118, 13:131, 13:135, 13:150, 13:262, 14:59, 14:86, 14:96, 14:153-14:154
16⁴	265 bp 50 bp 215 bp	430 bp	*03:100:01-03:100:02 *03:14-03:15:01:02, 03:90, 03:145, 03:185 *03:132	*11:208 *01:90, 04:98:01-04:98:02, 11:105, 14:107, 14:111, DRB3*01:82, DRB3*02:137N
17⁴	100 bp 230 bp 255 bp	430 bp	*03:93 *03:34 *03:20, 03:100:01- 03:100:02, 03:145	*13:125 *11:06:01-11:06:03, 11:21, 11:47, 11:57, 11:129, 11:174, 11:208, 13:58, 13:81, 13:163, 13:242:01-13:242:02, 13:284, 14:29, 14:99
18⁴	120 bp	430 bp	*03:01:01:01-03:01:41, 03:04:01-03:05:03, 03:07:01:01-03:10, 03:12-03:15:01:02, 03:16, 03:18-03:23, 03:25:01-03:25:02, 03:28-03:30, 03:32- 03:34, 03:36-03:37, 03:39-03:40, 03:42- 03:52:02, 03:54-03:59, 03:61-03:73, 03:78- 03:79, 03:82-03:83, 03:86-03:87, 03:91- 03:94, 03:96, 03:98- 03:101, 03:104-03:114, 03:116-03:121, 03:123- 03:124, 03:127-03:130, 03:132-03:144, 03:146- 03:153, 03:156N, 03:159-03:166, 03:168- 03:173, 03:175, 03:178, 03:180-03:187, 03:189N-03:190, 03:192-03:203	*11:07:01-11:07:02, 11:103:01-11:103:02, 11:105, 11:125, 11:173, 15:25, DRB3*01:23, DRB3*01:46, DRB3*02:146
19⁴	100 bp	515 bp	*03:58, 03:65	*01:111, 04:15, 04:25, 04:36, 04:143, 04:299N, 08:04:01:01-08:04:01:05, 08:04:04-08:04:07, 08:06:01:01- 08:06:01:02, 08:20, 08:22, 08:28, 08:31, 08:54, 08:59, 08:67, 08:70, 08:75, 08:80, 08:83, 08:94, 08:98-08:99, 09:06, 11:03:01- 11:04:22, 11:06:01-11:06:03, 11:25, 11:35, 11:38, 11:40-11:41, 11:43:01:01-11:44,



0197

For *In Vitro* Diagnostic Use
MA123 v02 SSP PI Template
Date: March 2023, Rev. No:00

101.113-24/04 – including *Taq* polymerase

101.113-24u/04u – without *Taq* polymerase

Visit www.caredx.com for
“Instructions for Use” (IFU)

Lot No.: **7R2**

Lot-specific information

				11:46:01-11:47, 11:50, 11:54:01-11:56, 11:58:01-11:60, 11:63:01-11:63:02, 11:67, 11:76-11:78, 11:83-11:85, 11:88-11:89, 11:92, 11:102:01-11:102:02, 11:104, 11:113, 11:115-11:116, 11:123, 11:129, 11:135, 11:137-11:139, 11:146, 11:148, 11:151, 11:156, 11:160-11:161, 11:163, 11:165:01-11:165:02, 11:173-11:174, 11:176, 11:179-11:182, 11:187, 11:189-11:190, 11:194:01-11:194:02, 11:196, 11:198, 11:200-11:201, 11:203, 11:206-11:207, 11:209-11:211, 11:213-11:214, 11:216-11:218, 11:220-11:221, 11:223-11:224, 11:227, 11:229-11:231, 11:233, 11:241, 11:244, 11:246N, 11:249, 11:253, 11:255, 11:258, 11:260-11:261, 11:264, 11:282, 11:284, 11:287N-11:288, 11:297Q, 11:300-11:301N, 11:304, 11:306-11:307, 12:02:01:01-12:02:13, 12:13, 12:15, 12:18-12:21, 12:23, 12:26-12:27, 12:31N-12:33, 12:37, 12:42-12:45, 12:49-12:52, 12:55-12:57, 12:60N, 12:64-12:65, 12:67, 12:69, 12:71, 12:73-12:76, 12:78, 12:80-12:81, 12:85, 12:92-12:94, 12:97-12:98N, 12:100, 13:11:01-13:11:02, 13:18, 13:24:01:01-13:24:01:03, 13:42:01-13:42:02, 13:54, 13:75, 13:108, 13:111, 13:144, 13:150, 13:164, 13:169, 13:246, 13:284, 13:307, 14:15, 14:73, 14:105, 14:108, 14:128, 15:04, 15:50N, 15:88, 15:142, 15:147, 15:208, 16:15, 16:33-16:34, DRB4*01:83, DRB5*01:31, DRB5*01:43-01:44, DRB5*01:55, DRB5*02:04, DRB5*02:08, DRB5*02:26N
20⁴	75 bp 120 bp 215 bp 245 bp	430 bp	*03:25:01-03:25:02, 03:31, 03:75, 03:118 *03:28 *03:73 *03:68N	*11:80, 11:135, 11:142 DRB3*01:77N
21⁴	70 bp 150 bp	430 bp	*03:21, 03:30, 03:43 *03:42, 03:87	*11:10:01-11:10:02, 11:12:01 ^w , 11:12:02, 11:12:03 ^w , 11:13:01-11:13:02, 11:114 ^w , 11:179 ^w , 11:190, 11:191 ^w , 11:196 ^w , 11:202, 11:218, 12:05, 12:14-12:15, 12:56, 13:57, 13:64, 13:83, 13:107, 13:175, 13:195, 13:204 ^w , 13:250, 14:35, 14:65, 14:72, 14:138, 14:175, 14:187, 15:167, DRB3*01:23, DRB3*03:26 *11:30, 11:288, 13:67, 13:195, DRB3*01:23, DRB3*01:46, DRB3*02:32, DRB3*02:81, DRB3*02:146, DRB3*03:26
22^{4,5}	95 bp 215 bp	430 bp	*03:18 *03:48, 03:73	
23^{4,5}	65 bp 165 bp	430 bp	*03:09, 03:23 *03:19	DRB3*01:31
24⁴	65 bp	430 bp	*03:02:01:01-03:03, 03:27, 03:29, 03:38, 03:53, 03:74, 03:88,	*12:58 ^w , 13:15, 13:26:01-13:26:02, 13:53, 13:85, 13:104, 13:198, 13:235,



0197

For *In Vitro* Diagnostic Use
MA123 v02 SSP PI Template
Date: March 2023, Rev. No:00

101.113-24/04 – including *Taq* polymerase
101.113-24u/04u – without *Taq* polymerase

Visit www.caredx.com for
“Instructions for Use” (IFU)

Lot No.: **7R2**

Lot-specific information

			03:90, 03:101-03:103, 03:115, 03:119, 03:120 ^w , 03:131, 03:154, 03:167, 03:176, 03:179	14:02:01:01-14:03:02, 14:06:01-14:06:06, 14:12:01-14:13, 14:18-14:19, 14:24, 14:27:01-14:27:02, 14:29, 14:46-14:48, 14:51-14:52, 14:63, 14:67, 14:78, 14:81, 14:85, 14:89, 14:98, 14:106, 14:108-14:109, 14:115, 14:121, 14:135, 14:154, 14:165, 14:170, 14:174, 14:176-14:177, 14:194- 14:195N, 14:198, 14:200, 14:209, 14:212, 14:222N-14:223, 14:226, 14:239, 14:242, DRB3*01:71, DRB3*02:20, DRB3*03:10
25⁴	80 bp 170 bp 230 bp	430 bp	*03:13:01-03:13:02, 03:67N, 03:88 *03:22, 03:32 *03:69	DRB3*01:01:03, DRB3*01:75, DRB3*02:19
26⁴	115 bp	515 bp	*03:26, 03:33, 03:43- 03:44, 03:71:01- 03:71:02	*11:15:01:01-11:15:02, 11:44, 11:49:01- 11:50, 11:76, 11:85, 11:114, 11:127, 11:183, 11:196, 11:249, 11:273, 11:278, 11:286, 11:302, 13:34, 13:62, 13:64, 13:106, 13:136, 13:151, 13:174, 13:204, 13:216, 13:221, 13:250, 13:266, 14:41, 14:77, 14:97, 14:110, 14:218, 14:221, DRB3*01:14
27⁴	115 bp	515 bp	*03:43, 03:71:01- 03:71:02	*11:15:01:01-11:15:02, 11:76, 11:114, 11:183, 11:196, 11:302, 13:34, 13:62, 13:64, 13:136, 13:151, 13:174, 13:204, 13:221, 13:250, 14:41, 14:77, 14:110, 14:218, DRB3*01:14
	150 bp 175 bp 235 bp		*03:53 *03:46, 03:130 *03:34, 03:55	*14:150
28⁴	75 bp 155 bp 195 bp	430 bp	*03:67N *03:36, 03:124 *03:45	*04:02:07, DRB5*01:04[?]
29	155 bp	430 bp	*03:22, 03:25:02, 03:40- 03:41:02, 03:52:01, 03:75, 03:105, 03:118, 03:155 *03:39 *03:92	*11:07:01-11:07:02, 11:103:01-11:103:02, 11:105, 11:107, 11:125, 11:173
	180 bp 215 bp			*14:76, 14:79
30	175 bp	430 bp	*03:01:01:01-03:07:02, 03:09, 03:11:01, 03:11:03-03:41:02, 03:43-03:45, 03:47- 03:63, 03:66-03:68N, 03:70-03:86, 03:88- 03:91, 03:93-03:110, 03:112-03:129, 03:131- 03:139, 03:141-03:155, 03:157-03:161, 03:163- 03:172, 03:174N- 03:188, 03:191-03:203	*08:20, 11:264, 13:01:01:01-13:16:01:02, 13:18-13:42:02, 13:44, 13:46-13:66:02, 13:68-13:102, 13:104-13:115, 13:117:01:01- 13:121, 13:123-13:158:02, 13:161-13:164, 13:166-13:174, 13:176-13:178, 13:180- 13:182, 13:184-13:190, 13:192-13:194, 13:196-13:213, 13:215-13:216, 13:218- 13:227, 13:229-13:247, 13:249N-13:298N, 13:300-13:332, 14:02:01:01-14:03:02, 14:05:01:01-14:06:06, 14:09, 14:12:01- 14:14, 14:17-14:21, 14:23:01:01-14:24, 14:27:01-14:27:02, 14:29-14:30, 14:33, 14:36-14:37, 14:40-14:45, 14:47-14:48, 14:51, 14:56, 14:59, 14:63-14:65, 14:67, 14:77-14:78, 14:80-14:81, 14:83-14:85, 14:89, 14:91, 14:94-14:96, 14:98, 14:100- 14:103, 14:106, 14:108-14:109,



0197

For *In Vitro* Diagnostic Use
MA123 v02 SSP PI Template
Date: March 2023, Rev. No:00

101.113-24/04 – including *Taq* polymerase

101.113-24u/04u – without *Taq* polymerase

Visit www.caredx.com for
“Instructions for Use” (IFU)

Lot No.: **7R2**

Lot-specific information

				14:115-14:116, 14:121, 14:123, 14:127:01-14:127:02, 14:134-14:136, 14:144, 14:154-14:156, 14:159-14:161, 14:165, 14:167, 14:169-14:170, 14:174, 14:176-14:179, 14:181, 14:183, 14:187-14:188N, 14:194-14:195N, 14:198, 14:209, 14:212, 14:218, 14:221, 14:223, 14:226, 14:239, 14:242, 14:246, DRB3*01:14
31	205 bp 245 bp	515 bp	*03:45, 03:92 *03:50	*14:76, 14:79
32⁷			Negative Control	

¹Alleles are assigned by the presence of specific PCR product(s). However, the sizes of the specific PCR products may be helpful in the interpretation of DRB1*03 SSP subtypings.

When the primers in a primer mix can give rise to HLA-specific PCR products of more than one length this is indicated if the size difference is more than 20 base pairs. Size differences of 20 base pairs or less are not given. For high resolution SSP kits, the alleles listed are specified according to amplicon length.

Nonspecific amplifications, i.e. a ladder or a smear of bands, may sometimes be seen. GC-rich primers have a higher tendency of giving rise to nonspecific amplifications than other primers.

PCR fragments longer than the control bands may sometimes be observed. Such bands should be disregarded and do not influence the interpretation of the SSP typings.

PCR fragments migrating faster than the control bands, but slower than a 400 bp fragment may be seen in some gel read-outs. Such bands can be disregarded and do not influence the interpretation of the SSP typings.

Some primers may give rise to primer oligomer artifacts. Sometimes this phenomenon is an inherent feature of the primer pair(s) of a primer mix. More often it is due to other factors such as too low amount of DNA in the PCR reactions, taking too long time in setting up the PCR reactions, working at elevated room temperature or using thermal cyclers that are not pre-heated.

²The internal positive control primer pairs amplify segments of the human growth hormone gene. The internal positive control bands are 430 or 515 base pairs respectively, well distribution as outlined in the table. Well number 1 contains the longer, 515 bp, internal positive control band. The well distribution of the internal controls can help in orientation of the kit on gel photo, as well as allow for kit identification. In the presence of a specific amplification the intensity of the control band often decreases.

³For several DRB1 alleles 1st and/or 3rd exon(s) and beyond, as well as intron nucleotide sequences, are not available. In these instances it is not known whether some of the primers of the SSP sets are completely matched with the target sequences or not. Assumption is made that unknown sequences in these regions are conserved within allelic groups.

⁴HLA-specific PCR products shorter than 125 base pairs have a lower intensity and are less sharp than longer PCR products.

⁵Primer mixes 6, 22 and 23 may have a tendency of giving rise to primer oligomer formation.

⁶Primer mix 2 may give rise to a lower yield of specific PCR product than the other DRB1*03 primer mixes.

⁷Primer mix 32 contains a negative control, which will amplify a majority of HLA amplicons as well as the amplicons generated by the control primer pairs matching the human growth hormone gene. HLA-specific PCR product sizes range from 75 to 200 base pairs and the PCR product generated by the HGH positive control primer pair is 200 base pairs.

Abbreviations

“?”, nucleotide sequence information not available for the primer matching sequence.

“w”, may be weakly amplified.



0197

For *In Vitro* Diagnostic Use
MA123 v02 SSP PI Template
Date: March 2023, Rev. No:00

101.113-24/04 – including *Taq* polymerase
101.113-24u/04u – without *Taq* polymerase

Visit www.caredx.com for
“Instructions for Use” (IFU)

Lot No.: **7R2**

Lot-specific information

PRIMER SPECIFICATION

Well No.	1	2	3	4	5	6	7	8	9	10	11	12
Length of spec.	220	85	155	190	75	105	125	185	135	145	100	135
PCR product			190				150				125	190
							215				180	
Length of int. pos. control ¹	515	430	515	515	430	430	430	430	430	430	515	430
5'-primer(s) ²	26(164) 5'-gTA 3'	13(125) 5'-gTC 3'	37(196) 5'-AgA 3'	37(196) 5'-AgA 3'	26(164) 5'-gTA 3'	26(164) 5'-gTA 3'	26(164) 5'-gTA 3'	26(164) 5'-gTT 3'	26(164) 5'-gTA 3'	13(125) 5'-gTC 3'	13(125) 5'-gTC 3'	26(164) 5'-gTA 3'
							112(423) 5'-CAT 3'					
3'-primer(s) ³	86(344) 5'-CCA 3'	28(171) 5'-CTC 3'	74(308) 5'-CCT 3'	86(344) 5'-CCA 3'	37(197) 5'-Cgg 3'	47(227) 5'-ggA 3'	54(247) 5'-CCg 3'	74(308) 5'-CCC 3'	57(257) 5'-CAT 3'	47(227) 5'-ggT 3'	31(179) 5'-ggC 3'	57(257) 5'-CAG 3'
			86(344) 5'-CAC 3'			48(229) 5'-CCT 3'	58(260) 5'-CCT 3'		57(257) 5'-CAT 3'		34(188) 5'-CCC 3'	57(257) 5'-CAG 3'
						48(229) 5'-CCA 3'	149(534) 5'-TTC 3'		57(258) 5'-gCg 3'		40(207) 5'-TCT 3'	74(308) 5'-CCg 3'
							170(595) 5'-AAg 3'				60(266) 5'-Agg 3'	79(324) 5'-CTC 3'
Well No.	1	2	3	4	5	6	7	8	9	10	11	12

Well No.	13	14	15	16	17	18	19	20	21	22	23	24
Length of spec.	125	105	95	50	100	120	100	75	70	95	65	65
PCR product	160	135	155	215	230			120	150	215	165	
	225	245	265		255			215		245		
Length of int. pos. control ¹	430	515	430	430	430	430	515	430	430	430	430	430
5'-primer(s) ²	13(125) 5'-gTC 3'	26(164) 5'-gTA 3'	13(125) 5'-gTC 3'	74(308) 5'-CCg 3'	13(125) 5'-gTC 3'	47(227) 5'-gTT 3'	67(286) 5'-ACT 3'	26(164) 5'-gTA 3'	10(116) 5'-gCT 3'	26(164) 5'-gTA 3'	26(164) 5'-gTA 3'	28(171) 5'-gAg 3'
				112(423) 5'-CAT 3'		47(227) 5'-ATT 3'			37(197) 5'-gTT 3'			
									37(197) 5'-gTT 3'			
3'-primer(s) ³	40(207) 5'-TCT 3'	48(229) 5'-CCA 3'	31(179) 5'-ggC 3'	77(317) 5'-Agg 3'	32(182) 5'-TAC 3'	73(305) 5'-ggC 3'	86(344) 5'-CCA 3'	37(196) 5'-gTA 3'	47(227) 5'-ggA 3'	45(220) 5'-CCg 3'	34(188) 5'-CCC 3'	37(196) 5'-gTT 3'
	52(241) 5'-CTg 3'	57(256) 5'-gCT 3'	51(239) 5'-CCC 3'	77(317) 5'-Agg 3'	76(313) 5'-gTT 3'			52(241) 5'-CTT 3'		84(337) 5'-CCg 3'	67(286) 5'-gAT 3'	
	56(254) 5'-CAC 3'	57(257) 5'-CAg 3'	52(241) 5'-CTg 3'	170(595) 5'-AAg 3'	85(341) 5'-CAg 3'			84(337) 5'-CCg 3'		85(340) 5'-AAT 3'		
	74(308) 5'-CCT 3'	94(367) 5'-TCA 3'	88(351) 5'-AAT 3'		88(351) 5'-AAT 3'			94(367) 5'-TCA 3'				
Well No.	13	14	15	16	17	18	19	20	21	22	23	24



0197

For *In Vitro* Diagnostic Use
MA123 v02 SSP PI Template
Date: March 2023, Rev. No:00

101.113-24/04 – including *Taq* polymerase

101.113-24u/04u – without *Taq* polymerase

Lot No.: **7R2**

Lot-specific information

Visit www.caredx.com for
“Instructions for Use” (IFU)

Well No.	25	26	27	28	29	30	31
Length of spec.	80	115	115	75	155	175	205
PCR product	170		150	155	180		245
	230		175	195	215		
			235				
Length of int.	430	515	515	430	430	430	515
pos. control ¹							
5'-primer(s) ²	11(118) 5'-ACg 3'	13(125) 5'-gTC 3'	13(125) 5'-gTC 3'	21(149) 5'-gAT 3'	16(133) 5'-gTT 3'	13(125) 5'-gTC 3'	6(103) 5'-CAg 3'
	27(166) 5'-ACg 3'			33(186) 5'-AAA 3'	27(167) 5'-CCg 3'		16(133) 5'-gTT 3'
	32(181) 5'-TCg 3'			61(269) 5'-CTA 3'	32(181) 5'-TCg 3'		21(149) 5'-gAT 3'
	60(266) 5'-gTC 3'			112(423) 5'-CAT 3'	34(189) 5'-CAA 3'		
	61(269) 5'-CTA 3'						
3'-primer(s) ³	73(305) 5'-ggC 3'	38(199) 5'-CAg 3'	38(199) 5'-CAA 3'	73(305) 5'-ggC 3'	73(305) 5'-ggC 3'	58(260) 5'-CAg 3'	73(305) 5'-ggC 3'
		38(199) 5'-CAA 3'	38(199) 5'-CAg 3'	149(534) 5'-TTC 3'		58(260) 5'-Cgg 3'	
		38(200) 5'-gCg 3'	49(232) 5'-Cgg 3'			58(260) 5'-CCg 3'	
			58(260) 5'-CgC 3'			59(264) 5'-TAT 3'	
			76(313) 5'-gTT 3'				
			80(326) 5'-gTA 3'				
Well No.	25	26	27	28	29	30	31

¹The internal positive control primer pairs amplify segments of the human growth hormone gene. The internal positive control bands are 430 or 515 base pairs respectively, well distribution as outlined in the table. Well number 1 contains the longer, 515 bp, internal positive control band. The well distribution of the internal controls can help in orientation of the kit on gel photo, as well as allow for kit identification. In the presence of a specific amplification the intensity of the control band often decreases.

²The nucleotide position matching the specificity-determining 3'-end of the primer is given. Nucleotide numbering as on the www.ebi.ac.uk/imgt/hla web site. The sequence of the 3 terminal nucleotides of the primer is given.

³The nucleotide position matching the specificity-determining 3'-end of the primer is given in the anti-sense direction. Nucleotide numbering as on the www.ebi.ac.uk/imgt/hla web site. The sequence of the 3 terminal nucleotides of the primer is given.



0197

For *In Vitro* Diagnostic Use
MA123 v02 SSP PI Template
Date: March 2023, Rev. No:00

101.113-24/04 – including *Taq* polymerase
101.113-24u/04u – without *Taq* polymerase

Visit www.caredx.com for
“Instructions for Use” (IFU)

Lot No.: **7R2**

Lot-specific information

CELL LINE VALIDATION SHEET																			
DRB1*03 SSP subtyping ²																			
				Well															
				1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16
				202134601	202348902	202134603	202134604	202134605	202134606	202134607	202134608	202134609	202134610	202134611	202134612	202134613	202134614	202134615	202134616
IHWC cell line ¹		DRB1		Prod. No.:															
1	9001	SA	*01:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
2	9280	LK707	*15:02	*04:05	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
3	9011	E4181324	*15:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
4	9275	GU373	*03:01		+	-	-	+	-	+	-	-	+	-	-	-	-	-	-
5	9009	KAS011	*16:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
6	9353	SM	*04:07	*08:03	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
7	9020	QBL	*03:01		+	-	-	+	-	+	-	-	+	-	-	-	-	-	-
8	9025	DEU	*04:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
9	9026	YAR	*04:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10	9107	LKT3	*04:05		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
11	9051	PITOUT	*07:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
12	9052	DBB	*07:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
13	9004	JESTHOM	*01:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
14	9071	OLGA	*08:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
15	9075	DKB	*09:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
16	9037	SWEIG007	*11:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
17	9282	CTM3953540	*03:01	*13:01	+	-	-	+	-	+	-	-	+	-	-	-	-	-	-
18	9257	32367	*09:01	*11:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
19	9038	BM16	*12:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
20	9059	SLE005	*13:02		-	-	+	-	-	-	-	-	-	-	-	-	-	-	-
21	9064	AMALA	*14:02		-	+	+	-	-	-	-	-	-	+	-	-	-	-	-
22	9056	KOSE	*13:02	*14:01	-	-	+	-	-	-	-	-	-	-	+	-	-	-	-
23	9124	IHL	*08:03	*14:14	-	-	-	-	-	-	-	-	-	-	+	-	-	-	-
24	9035	JBUSH	*11:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
25	9049	IBW9	*07:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
26	9285	WT49	*03:01		+	-	-	+	-	+	-	-	+	-	-	-	-	-	-
27	9191	CH1007	*04:05	*10:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
28	9320	BEL5GB	*04:16	*07:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
29	9050	MOU	*07:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
30	9021	RSH	*03:02		-	+	+	-	-	-	-	+	-	+	-	-	-	-	-
31	9019	DUCAF	*03:01		+	-	-	+	-	+	-	-	+	-	-	-	-	-	-
32	9297	HAG	*13:03		-	-	-	-	-	-	-	-	-	+	-	-	-	-	-
33	9098	MT14B	*04:04		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
34	9104	DHIF	*11:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
35	9302	SSTO	*04:03		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
36	9024	KT17	*04:03	*04:06	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
37	9065	HHKB	*13:01		-	-	-	+	-	-	-	-	-	-	-	-	-	-	-
38	9099	LZL	*14:02		-	+	+	-	-	-	-	-	-	+	-	-	-	-	-
39	9315	CML	*03:01	*04:01	+	-	-	+	-	+	-	-	+	-	-	-	-	-	-
40	9134	WHONP199	*07:01	*09:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
41	9055	H0301	*13:02		-	-	+	-	-	-	-	-	-	-	-	-	-	-	-
42	9066	TAB089	*08:03		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
43	9076	T7526	*09:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
44	9057	TEM	*14:01		-	-	-	-	-	-	-	-	-	+	-	-	-	-	-
45	9239	SHJO	*07:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
46	9013	SCHU	*15:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
47	9045	TUBO	*11:04	*12:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
48	9303	TER-ND	*01:03		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-



0197

For *In Vitro* Diagnostic Use
MA123 v02 SSP PI Template
Date: March 2023, Rev. No:00

101.113-24/04 – including *Taq* polymerase
101.113-24u/04u – without *Taq* polymerase

Visit www.caredx.com for
“Instructions for Use” (IFU)

Lot No.: **7R2**

Lot-specific information

CELL LINE VALIDATION SHEET																		
DRB1*03 SSP subtyping²																		
				Well														
				17	18	19	20	21	22	23	24	25	26	27	28	29	30	31
				202134617	202134618	202134619	202134620	202134621	202134622	202134623	202134624	202134625	202134626	202134627	202134628	202134629	202134630	202134631
IHWC cell line¹		DRB1		Prod. No.:														
1	9001	SA	*01:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
2	9280	LK707	*15:02	*04:05	-	-	-	-	-	-	-	-	-	-	-	-	-	-
3	9011	E4181324	*15:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-
4	9275	GU373	*03:01		-	+	-	-	-	-	-	-	-	-	-	-	-	-
5	9009	KAS011	*16:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-
6	9353	SM	*04:07	*08:03	-	-	-	-	-	-	-	-	-	-	-	-	-	-
7	9020	QBL	*03:01		-	+	-	-	-	-	-	-	-	-	-	-	-	-
8	9025	DEU	*04:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-
9	9026	YAR	*04:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-
10	9107	LKT3	*04:05		-	-	-	-	-	-	-	-	-	-	-	-	-	-
11	9051	PITOUT	*07:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-
12	9052	DBB	*07:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-
13	9004	JESTHOM	*01:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-
14	9071	OLGA	*08:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-
15	9075	DKB	*09:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-
16	9037	SWEIG007	*11:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-
17	9282	CTM3953540	*03:01	*13:01	-	+	-	-	-	-	-	-	-	-	-	-	-	-
18	9257	32367	*09:01	*11:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-
19	9038	BM16	*12:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-
20	9059	SLE005	*13:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-
21	9064	AMALA	*14:02		-	-	-	-	-	-	+	-	-	-	-	-	-	-
22	9056	KOSE	*13:02	*14:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-
23	9124	IHL	*08:03	*14:14	-	-	-	-	-	-	-	-	-	-	-	-	-	-
24	9035	JBUSH	*11:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-
25	9049	IBW9	*07:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-
26	9285	WT49	*03:01		-	+	-	-	-	-	-	-	-	-	-	-	-	-
27	9191	CH1007	*04:05	*10:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-
28	9320	BEL5GB	*04:16	*07:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-
29	9050	MOU	*07:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-
30	9021	RSH	*03:02		-	-	-	-	-	-	+	-	-	-	-	-	-	-
31	9019	DUCAF	*03:01		-	+	-	-	-	-	-	-	-	-	-	-	-	-
32	9297	HAG	*13:03		-	-	-	-	-	-	-	-	-	-	-	-	-	-
33	9098	MT14B	*04:04		-	-	-	-	-	-	-	-	-	-	-	-	-	-
34	9104	DHIF	*11:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-
35	9302	SSTO	*04:03		-	-	-	-	-	-	-	-	-	-	-	-	-	-
36	9024	KT17	*04:03	*04:06	-	-	-	-	-	-	-	-	-	-	-	-	-	-
37	9065	HHKB	*13:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-
38	9099	LZL	*14:02		-	-	-	-	-	-	+	-	-	-	-	-	-	-
39	9315	CML	*03:01	*04:01	-	+	-	-	-	-	-	-	-	-	-	-	-	-
40	9134	WHONP199	*07:01	*09:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-
41	9055	H0301	*13:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-
42	9066	TAB089	*08:03		-	-	-	-	-	-	-	-	-	-	-	-	-	-
43	9076	T7526	*09:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-
44	9057	TEM	*14:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-
45	9239	SHJO	*07:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-
46	9013	SCHU	*15:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-
47	9045	TUBO	*11:04	*12:01	-	-	+	-	-	-	-	-	-	-	-	-	-	-
48	9303	TER-ND	*01:03		-	-	-	-	-	-	-	-	-	-	-	-	-	-



0197

For *In Vitro* Diagnostic Use
MA123 v02 SSP PI Template
Date: March 2023, Rev. No:00

101.113-24/04 – including *Taq* polymerase

101.113-24u/04u – without *Taq* polymerase

Lot No.: **7R2**

Visit www.caredx.com for
“Instructions for Use” (IFU)

Lot-specific information

¹The provided cell line HLA specificities are retrieved from the <http://www.ihwg.org/hla> web site. The specificity of an individual cell line may thus be subject to change.

²The specificity of each primer solution in the kit has been tested against 48 well characterized cell line DNAs and where applicable, additional cell line DNAs.

No DNAs carrying the alleles to be amplified by primer solutions 7, 11 to 17, 20 to 23, 25 to 29 and 31 were available. The specificities of the primers in primer solutions 7, 11 to 17, 21, 26 to 29 and 31 were tested by separately adding one, two or three additional 5'-primers, respectively one or two additional 3'-primers. In primer solutions 25 it was only possible to test the 3'-primer, the 5'-primers were not possible to test. In primer solutions 20, 22 and 23 it was only possible to test the 5'-primers, the 3'-primers were not possible to test.

In primer solutions 6, 7, 11 to 17, 27 and 30 one or more of the 3'-primers were not possible to test. In primer solutions 18, 21, 28, 29 and 31 one or more of the 5'-primers were not possible to test. In primer solutions 3 and 9 one or two additional 3'-primer was tested by adding one or two additional 5'-primers.



0197

For *In Vitro* Diagnostic Use
MA123 v02 SSP PI Template
Date: March 2023, Rev. No:00

101.113-24/04 – including *Taq* polymerase

101.113-24u/04u – without *Taq* polymerase

Lot No.: **7R2**

Lot-specific information

Visit www.caredx.com for
“Instructions for Use” (IFU)

ADDRESSES:

Manufacturer:

CareDx AB, Franzengatan 5, SE-112 51 Stockholm, Sweden.

Tel: +46-8-508 939 00

Fax: +46-8-717 88 18

E-mail: orders-se@caredx.com

Web page: www.caredx.com

Distributed by:

CareDx Lab Solutions Inc., 901 S. Bolmar St., Suite R, West Chester, PA 19382

Tel: 1-877-653-78171

Fax: 610-344-7989

E-mail: orders-us@caredx.com

Web page: www.caredx.com

For information on CareDx distributors worldwide, contact **CareDx AB**.



0197

For *In Vitro* Diagnostic Use

MA123 v02 SSP PI Template

Date: March 2023, Rev. No:00